Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mouret

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 22, 2022
Corrigendum to "De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis" [Eur J Cancer 158 (2021) 181-188]T Gaillard, M Carton, A Mailliez, et al.
Breast (Edinburgh, Scotland)|November 2, 2019
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC databaseP Gougis, M Carton, C Tchokothe, et al.
ESMO Open|May 13, 2021
Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life databaseM Carausu, M Carton, A Darlix, et al.
British Journal of Cancer|April 3, 2023
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutationJ-S Frenel, A Lusque, S Delaloge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2018
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancerP Cottu, V D'Hondt, S Dureau, et al.
Breast Cancer Research and Treatment|January 5, 2022
Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohortM Bringuier, M Carton, C Levy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2016
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational studyS Delaloge, D Pérol, C Courtinard, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2020
Palliative care delivery according to age in 12,000 women with metastatic breast cancer: Analysis in the multicentre ESME-MBC cohort 2008-2016Matthieu Frasca, Camille Sabathe, Suzette Delaloge, et al.
ESMO Open|April 25, 2021
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohortT Grinda, A Antoine, W Jacot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumabJ-Y Pierga, F-C Bidard, A Autret, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|March 22, 2022
Corrigendum to "De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis" [Eur J Cancer 158 (2021) 181-188]T Gaillard, M Carton, A Mailliez, et al.
Breast (Edinburgh, Scotland)|November 2, 2019
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC databaseP Gougis, M Carton, C Tchokothe, et al.
ESMO Open|May 13, 2021
Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life databaseM Carausu, M Carton, A Darlix, et al.
British Journal of Cancer|April 3, 2023
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutationJ-S Frenel, A Lusque, S Delaloge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2018
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancerP Cottu, V D'Hondt, S Dureau, et al.
Breast Cancer Research and Treatment|January 5, 2022
Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohortM Bringuier, M Carton, C Levy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2016
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational studyS Delaloge, D Pérol, C Courtinard, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2020
Palliative care delivery according to age in 12,000 women with metastatic breast cancer: Analysis in the multicentre ESME-MBC cohort 2008-2016Matthieu Frasca, Camille Sabathe, Suzette Delaloge, et al.
ESMO Open|April 25, 2021
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohortT Grinda, A Antoine, W Jacot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumabJ-Y Pierga, F-C Bidard, A Autret, et al.
Pageof 6